CAMBRIDGE, Mass., Jan 09, 2014 (BUSINESS WIRE) -- Mersana Therapeutics, Inc. announced today that it has achieved its second preclinical milestone in its collaboration with Endo Pharmaceuticals ENDP 0 ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mersana Therapeutics, Inc., a clinical-stage biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its ...

CAMBRIDGE, Mass.--January 12, 2015--Mersana Therapeutics, Inc. announced today that they have expanded their ongoing collaboration with Takeda Pharmaceutical Company Limited (TSE:4502) to create novel ...

Cambridge, Mass. and Osaka, Japan, February 3, 2016 – Mersana Therapeutics and Takeda Pharmaceutical Company Limited (TSE:4502) today announced that they have entered a new strategic partnership ...

The proceeds from this financing will be used to advance Mersana's Fleximer-based ADC technology and to generate a pipeline of proprietary next-generation ADCs. In conjunction with the investment, NEA ...

Mersana Therapeutics and Merck KGaA’s EMD Serono subsidiary will team up to develop antibody-drug conjugates (ADCs) using Mersana’s Fleximer® technology. The deal could net Mersana up to $792 million ...

CAMBRIDGE, Mass., March 7, 2012 /PRNewswire/ -- Mersana Therapeutics, Inc. announced today that it has entered into a collaboration agreement with Endo Pharmaceuticals (Nasdaq: ENDP) to develop ...

About Fleximer ( (R)) Antibody-Drug Conjugate TechnologyMersana's next-generation Fleximer ( (R)) antibody-drug conjugate (ADC) technology is based on the Company's proprietary biodegradable polymer ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mersana Therapeutics, Inc. announced today that it successfully achieved the first preclinical milestone in its collaboration with Endo Pharmaceuticals (Nasdaq: ENDP ...

"Using antibodies and other targeting agents to deliver potent drugs to the site of tumors and disease while avoiding off-target toxicities has long been pursued almost as a holy grail in the ...

Beyond development and commercialization of XMT-1522, the expanded partnership also grants Takeda access to additional targets within Mersana’s Fleximer-based ADC platform, with Mersana retaining the ...